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PENYARINGAN UGT1A1 GEN DAN HUBUNGKAIT GENOTIP-
PENOTIPIK DALAM PENYAKIT KUNING DARIPADA SAMPLE BAYI 
BARU LAHIR DI KELANTAN 
ABSTRAK 
 
Proses pengeluaran bilirubin adalah melalui proses glukuronidasi bilirubin yang 
terletak pada hati dan proses ini dimangkinkan oleh sejenis enzim iaitu Uridine 
glucuronosil transferase. Enzim ini dikodkan oleh gen iaitu gen UGT1A1. Dalam 
sesetengah populasi, mutasi pada gen ini akan menyebabkan berlakunya demam 
kuning. Walau bagaimanapun, data bagi populasi Melayu di Malaysia kurang diberi 
perhatian. Objektif kajan ini meliputi: mengetahui peratusan variasi pada ekson pada 
gen UGT1A1 dalam  populasi Melayu yang menghidap demam kuning atau tanpa 
demam kuning serta untuk menghubungkaitkan penemuan dari segi genotip dan data 
Penotipik. Kajian keratin rentas dilakukan di Kelantan, Malaysia. Kumpulan 
disahkan sebagai bayi dengan demam kuning (kumpulan demam kuning) dan 
kumpulan bayi tanpa demam kuning (kumpulan kawalan) terlibat dalam kajian ini. 
Darah diambil untuk ujian genetik. DNA diekstrak daripada darah sebelum kaedah 
tindak balas berantai polimerase (PCR) dilakukan. Kromatografi cecair denaturasi 
berprestasi tinggi (DHPLC) dilakukan bagi menyaring keseluruhan ekson di dalam 
UGT1A1 gen dan subjek yang dikenal pasti mengandungi bentuk ganda dua pada 
graf DHPLC, akan melakukan proses penjujukan DNA bagi mengesahkan kehadiran 
mutasi atau SNP. Data klinikal di ambil sebagai sebahagian daripada kajian yang 
besar yang di jalankan. Data dimasukkan melalui SPSS dan dianalisis. 286 bayi 
terlibat di dalam setiap kumpulan, kumpulan demam kuning dan kumpulan kawalan. 
Sembilan variasi telah di temui dalam kajian ini. Variasi yang paling kerap ialah 
xx 
 
G71R pada ekson 1, yang kerap ditemui pada populasi Asia yang lain. Hanya 4 
daripada varisi itu pernah dilaporkan sebagai SNPs pada populasi yang lain. 
Manakala variasi yang lain, di laporkan sebagai mutasi yang baru. Walaupun banyak 
variasi dilaporkan pada kumpulan demam kuning berbanding kumpulan kawalan, 
namun tiada perbezaan secara statistik antara kedua-dua kumpulan secara 
statistiknya adalah saling tidak berkaitan. Kajian ini juga menunjukkan tiada kaitan 
antara kehadiran faktor penyakit kuning pada bayi dan hemolitik antara bayi kuning 
dengan dan tanpa variasi dalam UGT1A1 gen. G71R telah dikenal pasti sebagai 
variasi yang utama dalam UGT1A1 gen. Keputusan kajian ini masih belum 
menunujukan dengan jelas faktor menyebabkan berlakunya demam kuning.       
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SCREENING OF UGT1A1 GENE AND THE GENOTYPE-PHENOTYPE 
CORRELATIONSHIP IN NEONATAL JAUNDICE FROM A SAMPLE OF 
NEWBORNS IN KELANTAN 
ABSTRACT 
 
The rate limiting step of bilirubin excretion is the glucuronidation of bilirubin in the 
liver, a process that is catalyzed by an enzyme, Uridine glucuronyl transferase. This 
enzyme is encoded by the UGT1A1 gene. In several populations, mutations in this 
gene have been shown to cause neonatal jaundice. However data on the Malaysian 
Malay population are scanty at best. The objectives of this study included: to 
determine the frequency of variants in the exons of the UGT1A1 gene in a 
population of term Malay neonates with jaundice and without jaundice, and to 
correlate the genotype finding with some phenotypic data. A cross sectional study 
was performed in Kelantan, Malaysia. A group of term jaundiced neonate (jaundice 
group) and a group of term non-jaundiced neonate (control group) were included in 
the study. Blood was taken for genetic testing. DNA was extracted from blood 
before polymerase chain reaction (PCR) was performed. Denaturing high 
performance liquid chromatography (DHPLC) was performed to screen the whole 
exons in the UGT1A1 gene and for subjects that were identified to have a 
heteroduplex peak in DHPLC, sequencing was performed to confirm the mutation or 
SNP. Clinical data were collected as part of a larger study. Data were entered in 
SPSS and analyzed. Two hundred and eighteen six (286) neonates were included in 
each the jaundice and control groups. Nine variants have been identified in this 
study. The most common variant was the G71R variant in exon 1, which is common 
xxii 
 
in other Asian populations as well. Only 4 of the other variants detected in this study 
had been reported as SNPs in another population. Other variants appeared to be 
novel mutations. Even though variants were found in a higher number in the 
jaundice group than in the control group, the difference between the groups was 
statistically not significant. There were also no significant differences in severity of 
neonatal jaundice and in haemolysis between jaundiced neonates with and without 
identified variants in the UGT1A1 gene. The G71R variant had been identified as the 
most common variant in the exons of the UGT1A1 gene. The results of this study did 
not clearly show that this was a risk factor for neonatal jaundice.  
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CHAPTER 1 
 
 
INTRODUCTION 
 
1.1 Background of the study 
Neonatal jaundice (NNJ) is the most common reason for hospital admission of new 
born neonates. In the American population, neonatal jaundice (NNJ) was reported to 
occur with a frequency of 60% in full term neonates and 80% in premature neonates 
(Agarwal et al., 2007). An earlier study suggested that the incidence of neonatal 
jaundice was significantly lower among Americans from African ancestry compared 
to African populations that are living in Africa (Kaplan et al., 2008). This suggests 
that environmental factors may play an important role in the pathogenesis of 
neonatal jaundice. On the other hand, East Asians were reported to have a much 
higher incidence of severe neonatal jaundice than Caucasians (Yamamoto et al., 
2002) and this difference persisted in a population of East Asians for several 
generations after migration to the USA (Miller, 2008). These data suggest that the 
increased incidence of NNJ in East Asians is due to genetic factors. So both 
environmental and genetic factors may play an important role in the pathogenesis of 
NNJ (Ardakani et al., 2007) (Kaplan M et al., 2005).  
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Hemolytic factors such as ABO incompatibility, Rhesus incompatibility, and 
glucose-6-phosphate dehydrogenase (G6PD) deficiency are among the best known 
causes of NNJ. In Malaysia all neonates are screened for G6PD deficiency with the 
hope of preventing kernicterus and bilirubin encephalopathy through early detection 
and treatment of jaundice. Furthermore neonates with NNJ requiring hospitalization 
are screened for the presence of ABO incompatibility and signs of hemolysis in the 
blood film. Other well known causes of neonatal jaundice that are routinely looked 
for in the neonates with NNJ requiring therapy, include polycythaemia, birth trauma, 
low birth weight, prematurity, poor breast feeding (Fabris et al., 2009) and a positive 
family history (Rennie J et al., 2010). Still a lot of neonates get severe NNJ and 
without any of the above risk factors being clearly identified and these neonates are 
labelled to have idiopathic NNJ or excessive physiological NNJ. 
Several genetic risks may play an important role in this group with idiopathic NNJ. 
Mutations in a gene known as Uridine GlucuronosylTransferase 1A1 (UGT1A1) 
gene have been investigated as a genetic factor potentially contributing to NNJ. 
Mutations might appear either in the enhancer region, the promoter region, exons or 
introns. In the Caucasian population a particular mutation in the promoter region 
called A (TA)7TAA mutation is proven to be a risk factor for NNJ and results in a 
markedly reduced expression of the enzyme (Bosma et al., 1995). In some East 
Asian populations (Japan and South Korea) a mutation in exon 1 of the UGT1A1 
gene has been identified as a risk factor for NNJ and was associated with a close to 
60% expression of the enzyme (Yamamoto et al., 1998).  
In Malaysia, mutations in the UGT1A1 gene promoter and enhancer regions have 
been investigated and were shown to be significantly associated with NNJ (Yusoff S 
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et al., 2010). There are few reports of small studies in the Malay population looking 
at mutations in exons (Sutomo et al., 2004) (Yusoff et al., 2006).  Mutations in 
exons were also described by the same group of researchers in a Malay family 
resulting in a significant reduction of expression of the Uridine 
Glucuronosyltransferase (UGT) enzyme (Wada et al., 2006). 
The purpose of this study was to screen for mutations in the exons of the UGT1A1 
gene in a group of Malay neonates with neonatal jaundice and compare the 
incidence of such mutations between neonates with and without neonatal jaundice. 
Within the group of neonates with neonatal jaundice, an attempt was made to 
correlate the presence of exonic mutations with the severity of jaundice and signs of 
haemolysis. 
In the remaining part of the introduction of this thesis, subsequently, the following 
topics will be covered. Neonatal jaundice will be defined after which briefly the 
bilirubin metabolism and some clinical aspects of neonatal jaundice will be covered. 
After that the author will focus in on the UGT1A1 gene.    
1.2 Definition of Neonatal jaundice (NNJ) 
Neonatal jaundice is a yellow discoloration of the skin, mucosal membranes and 
white eye (sclera) in newborn neonates. It is related to an increase in serum bilirubin 
levels. Jaundice becomes apparent, only if the serum bilirubin levels increase to 
more than 90 μmol/L in the most cases. The jaundice usually starts in the face and 
progresses caudally as the serum bilirubin levels increase (Anthony and Stoll, 2007). 
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1.3 BILIRUBIN METABOLISM 
Red blood cells (RBC) are produced in bone marrow and destroyed in the spleen.  
When the RBC are lysed, haemoglobin (Hb), that contains heme and globin is 
released. The globin part is broken down into amino acids and the iron is released 
from the heme group. The heme group is converted to biliverdin and later to 
bilirubin (Maisels and Watchko, 2000). Every 1 gram of Hb produces 35mg of 
bilirubin (bilirubin is produced at 8.5±2.3mg/kg/24 hours) (Watchko, 2000). 
Bilirubin is a waste product of the heme metabolism. It is insoluble in water because 
of internal hydrogen bond interactions and it consists of four pyrrole and porphyrin 
rings (Fialova and Vejrazka, 2010). About 80% of the bilirubin molecules are 
derived from the catalysis of circulating haemoglobin (Hb).  While another 20% is 
originated from other heme containing proteins, for example P450s and myoglobin 
(Tukey and Strassburg, 2000). 
The bilirubin formed is unconjugated bilirubin (UB), which is lipid soluble. This 
molecule is transported in the plasma, bound to albumin to form bilirubin-albumin 
complex. When this bilirubin-albumin complex reaches to hepatocytes (liver cells), 
it will bind to the cell surface and bilirubin will be transported into the cell. In the 
liver, bilirubin will conjugate to glucuronic acid (making the molecule water 
soluble). This process is the rate limiting step in bilirubin excretion and is catalyzed 
by the uridine diphosphoglucuronyltransferase (UDPGT) enzyme. Only after 
conjugation it can be excreted into the bile to the small intestine. Some of 
conjugated bilirubin (CB) in the large intestine is metabolized to stercobilinogen 
before it is oxidized and changed to stercobilin which gives the brown colour to the 
faeces. Another part of the conjugated bilirubin is converted to urobilinogen which 
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is reabsorbed and excreted in the urine in an oxidized form, called urobilin. A 
fraction of bilirubin from the faeces will be reabsorbed into blood via portal 
circulation (enterohepatic circulation). During the foetal life in the mother‟s womb, 
bilirubin is eliminated through the placenta via the umbilical cord, while during 
neonates, the liver will eliminate it in the conjugated form of bilirubin before it is 
moved to the gastrointestinal tract (Hansen, 2000). 
If the unconjugated bilirubin (UB) does not excreted fast enough by the liver, the 
serum bilirubin will increase and bilirubin is deposited in tissues in the body leading 
to NNJ. This UB has the ability to cross the blood brain barrier (BBB) and cause 
kernicterus or bilirubin encephalopathy. Kernicterus appears when the level of 
serum bilirubin becomes too high and it can be confirmed during autopsy. It will 
give a yellow colour to the hippocampus, basal ganglia, nuclei of cerebellum and 
brain stem (Bhutani and L., 2005).  
In most of the cases, NNJ occurs due to unconjugated bilirubin formation that is 
caused by immaturity of hepatocytes leading to low activity of the UDPGT.  
Another factor of NNJ is the short life span of RBC (between 45-90 days) in 
neonates as compared to adults (about 120 days) that lead to overproduction of 
serum bilirubin in the neonates (Moerschel et al., 2008). Figure 1.2 and 1.3 shows 
the normal and abnormal bilirubin pathways respectively. 
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Red Blood Cells break down                                Hemoglobin                      Globin 
 
                     Presence of O2 & NADPH Heme                Haem oxygenase(HO) 
      
                         Biliverdin               Biliverdin reductase 
        
Bilirubin-albumin (Unconjugated Bilirubin)      Bilirubin   
 
 Liver (Glucuronisation) 
 
              Excreted in bile 
 
       Urobilinogen                              Reabsorbed large intestine             
 
           Stercobilinogen                                              Small amount-urine 
  
 Stercobilin (brown color in stool) 
 
Figure 1.1: Normal Pathway of bilirubin metabolism 
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 Red Blood Cell (RBC) breaks down                    Hemoglobin                    Globin 
 
                          Presence of O2 & NADPH   Heme                 Haem oxygenase(HO) 
       
               Biliverdin               Biliverdin reductase 
        
Bilirubin-albumin (Unconjugated Bilirubin)           Bilirubin   
 
     Unable to enter hepatocyte                     Unconjugated bilirubin surround cells  
(Bilirubin increase without excrete it) 
 
   If untreated 
 Possibility to enter Blood Brain Barrier (BBB) 
 
 
        Kernicterus/ Brain encephalopathy 
 
 
                       Mortality 
 
Figure 1.2: Abnormal Pathway in bilirubin metabolism 
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1.4 Clinical aspects of neonatal jaundice (NNJ) 
1.4.1 Unconjugated bilirubin (Indirect hyperbilirubinemia)  
Unconjugated bilirubin consists of lipid soluble or fat soluble molecules. Indirect 
hyperbilirubinemia occurs when the serum bilirubin level exceeds 34.2µmol/L.  
Indirect hyperbilirubinemia leads to accumulation of free bilirubin in certain parts of 
the body and most importantly it can cross the blood brain barrier (BBB) and 
accumulate in the brain leading to kernicterus and neurological disease. It is the 
small fraction of unconjugated bilirubin in the plasma that is not bound to albumin 
(unbound bilirubin) that can move into the brain.  Kernicterus was first described in 
1847 by Hervieux (Juretschke, 2005) and it was observed from tissues of the brain 
during an autopsy where the yellow staining had appeared. Presence of endogenous 
or exogenous binding competitors to albumin such as certain drugs can decrease 
binding affinity of albumin to bilirubin and increase the risk of kernicterus. 
1.4.2 Conjugated bilirubin (Direct hyperbilirubinemia)  
Conjugated bilirubin is identified as a water soluble molecule that moves through 
the bile duct to the intestine (Odell, 1980). The conjugation process involves the 
binding of 2 molecules of glucuronic acid to bilirubin, a process catalysed by the 
uridine glucuronosyl transferase (UGT). Direct hyperbilirubinaemia in the neonate is 
generally due to hepatocellular diseases and infectious or metabolic disorders (Klein 
et al., 2010).  
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1.5 Common causes of neonatal jaundice 
1.5.1 Physiological jaundice 
Physiological jaundice is a mild form of jaundice that occurs in almost 60% of term 
newborns and in about 70% of preterm neonates. It appears after 24 hours (within 48 
to 72 hours) of life (Saxena, 2008). The peak serum bilirubin levels are reached at 
the 3
rd
 or 4
th
 day of life for full term neonates and it disappears after 14 days of life. 
Usually, it is caused by a combination of increased bilirubin production due to a 
shorter lifespan of RBC containing foetal haemoglobin and immaturity of the liver 
leading to accumulation of unconjugated bilirubin. Physiological jaundice consists 
of two phases. In phase I serum bilirubin will rapidly increase in the first three days, 
while in phase II, it  will decreases slowly and reaches the normal range by day 11-
14 of life (Madan et al., 2005). Physiological jaundice is less severe than 
pathological jaundice.       
1.5.2 Pathological jaundice 
Another type of jaundice is pathological jaundice. This type of jaundice commonly 
appears in the first 24 hours of life (Jack, 2011) and requires treatment. It can be 
seen when serum bilirubin levels exceed the 95
th
 percentile as defined in a 
nomogram (Kaplan et al., 2006). 
Pathological jaundice can be caused by haemolytic and non-haemolytic (Kaplan et 
al., 2006) factors.  
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1.5.2.1 Haemolytic factors  
Factors associated with an increase in red blood cell (RBC) breakdown are many 
and include glucose-6-phosphate dehydrogenase (G6PD) deficiency, ABO 
incompatibility, Rhesus incompatibility, other blood group incompatibilities, 
polycythaemia, birth trauma, sickle cell anaemia, and other abnormalities of the 
RBC. In the next two subchapters a brief elaboration will be given on G6PD 
deficiency and ABO incompatibility. 
1.5.2.1 (i) Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency 
Glucose-6-phosphate dehydrogenase or G6PD is known as an RBC enzyme 
deficiency where the decrease of enzyme in the body might lead to haemolysis. The 
incidence of G6PD deficiency is higher in people from Africa, the Middle East, 
Arabian Peninsular, Mediterranean area and Southeast Asia including Thailand and 
Malaysia (Cappellini and Fiorelli, 2008). Since the 1980s, screening of G6PD in 
neonates has been practiced in Malaysia for early detection and treatment of 
neonatal jaundice and affected neonates will be observed in the ward (Ainoon et al., 
2003).  
The reduced form of nicotinamide adenine dinucleotide phosphate (NADPH) 
(Cappellini and Fiorelli, 2008) is used as a co-enzyme for G6PD which is useful to 
maintain the level of glutathione that will protect the RBC from oxidative stresses.  
One of the well known complications of G6PD deficiency is NNJ which usually 
starts on day 2 to 3 of life and can be very severe (Bhutani et al., 2004). In Malaysia, 
a study suggested a high incidence of G6PD deficiency in the Malay and Chinese 
populations (Singh, 1986). However it is lower in the Indian population. Its 
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incidence in males is much higher than in females because G6PD deficiency is an X-
linked recessive disorder (Garg et al., 1984).  
1.5.2.1 (ii) ABO Incompatibility    
ABO incompatibility cases commonly appear when a mother with blood group „O‟ 
is having or carrying a child with blood groups either „A‟ or „B‟ (Mourant, 1977). In 
neonates with ABO incompatibility, NNJ usually appears during the first 24 to 48 
hours of life (Bhutani et al., 2004) . However, ABO incompatibility not only occurs 
in neonates of mothers with „O‟ blood type. It also can happen if mothers with blood 
group A have neonates carrying blood group B and if mothers with blood group B 
have neonates carrying blood group A (Iannelli, 2006). 
A previous study by Kalakheti et al  reported that neonates with ABO 
incompatibility had a two times higher chance to get hyperbilirubinaemia compared 
to neonates with other haemolytic risk factors (Kalakheti et al., 2009).   
1.5.2.2 Non-hemolytic factors 
In few cases, neonatal jaundice may appear due to non-hemolytic factors. These 
conditions include: 
1. Inborn errors of metabolism such as Crigler- Najjar Syndrome types I, II and 
Gilbert Syndrome (Huang et al., 2001). These are described in more details 
below. 
2. Impaired bilirubin excretion leading to neonatal cholestasis, for example in 
Dubin-Johnson syndrome or infections such as urinary tract infection (UTI) 
and sepsis (MacDonald et al., 2005). 
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3. There are two types of NNJ related to breast feeding. One is breast feeding 
jaundice, which is related to inadequate milk intakes early in life and this is 
associated with early onset jaundice. A second type is breast milk jaundice, 
related to a substance present in breast milk (3-α-20β pregnanediol) that may 
cause NNJ in 1 to 2% of breastfed neonates.  NNJ symptoms usually start on 
day 4 to day 7 and can last 3 to 10 weeks, or even longer. Both types are 
associated with an increase in enterohepatic circulation (Schmitt, 2009). 
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Associated factors                                    Effect on neonatal serum bilirubin levels 
    Increase                                        Decrease                                     No effect  
Ethnicity East Asian 
Native American 
Greek 
African American - 
Genetic or familial Previous sibling with jaundice 
Variant promoter or mutation of 
UGT1A1 gene associated with 
Gilbert‟s syndrome 
 
- - 
Maternal Older mothers 
Diabetes 
Hypertension                                     
Oral contraceptive use at time of 
conception                                             
First-trimester bleeding 
Decreased plasma zinc level 
Smoking - 
Drugs administered to 
mother 
Oxytocin 
Diazepam 
Epidural anesthesia 
Promethazine 
Phenobarbital 
Meperidine 
Reserpine 
Aspirin 
Chloral hydrate 
Heroin 
Phenytoin 
Antipyrine 
Alcohol 
Beta-adrenergic agents 
Labor and delivery Premature rupture of membranes 
Forceps delivery 
Vacuum extraction 
Breech delivery 
- Fetal distress 
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Table 1.1 The factors associated with neonatal jaundice (Adapted from (Maisels and 
Watchko, 2000). 
 
 
 
 
 
 
 
 
 
 
Infant Low birth weight 
Low gestation 
Male gender 
Delayed cord clamping 
Elevated cord blood bilirubin level 
Delayed meconium passage 
Breast feeding 
Caloric deprivation 
Larger weight loss after birth 
Low serum zinc and magnesium 
- - 
Drugs administered to 
infant 
Chloral hydrate 
Pancuronium 
 
- - 
Other Altitude 
Short hospital stay afterbirth 
- - 
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1.6 Clinical syndromes associated with mutations in the UGT1A1 gene     
Gilbert syndrome (GS) and Crigler-Najjar syndrome (type I and type II) are the 
clinical syndromes which are commonly related to mutations in the UGT1A1 gene 
associated with NNJ. Many studies reported that a decreased activity of the uridine 
diphosphoglucuronosyltransferase enzyme (UDPGT) in the liver, resulting in 
increases of unconjugated bilirubin levels is due to mutations in the UGT1A1 gene 
(Bosma et al., 1995) (Strassburg and Manns, 2000). These clinical syndromes are 
classified into three forms based on serum bilirubin levels (Huang et al., 2001).  
- The most severe form is Crigler-Najjar syndrome type I (CN I).  
- Intermediate severity is seen in Crigler-Najjar syndrome type II (CN II).  
- The mildest form is Gilbert syndrome.  
In the Malay population reports about these clinical syndromes are scanty but 
mutations typically associated with Gilbert syndrome have been reported (Yusoff et 
al., 2006).  
1.6.1 Gilbert syndrome (GS) 
 GS was discovered in 1901 by Gilbert and Lereboullet, and was described as ``La 
cholemie simple familiale'' (Sampietro and Iolascon, 1999). GS is caused by a 
reduction in glucuronidation activity of the UGT1A1 enzyme in the liver by 25-50% 
from the normal range (Innocenti et al., 2002). Mutations in the UGT1A1 gene that 
may cause GS were only discovered in 1995 (Bosma et al., 1995). 
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GS is a benign condition with a mild form of often fluctuating hyperbilirubinaemia. 
It might involve a single or complex locus that encodes for the enzyme, bilirubin-
UDP-glucuronosyltransferase (Sampietro and Iolascon, 1999).  
In Malaysia, mutations in UGT1A1 that lead to GS were first reported in 2004 and 
they were found to be quite common (around 6.3%) in the studied Malay population 
(Sutomo R et al., 2004). 
Many studies showed that mutations of the UGT1A1 gene related to GS were 
commonly observed in the promoter region with addition of 2 base pairs (bp) of 
Thymine (T) and Adenine (A) nucleotide in an area known as TATA box (Iolascon 
A et al., 1999) (Beautler E et al., 1998). The normal repetition of TA is 6 and an 
addition of TA as seen in the A (TA)7TAA mutation, also known as UGT1A1*28, 
might lead to Gilbert syndrome. The addition of TA causes impairment of proper 
message transcription that can cause a decrease of UGT1A1 activity in the liver 
(Bosma et al., 1995). 
A study from Scotland also suggested that GS not only contributed to prolonged 
jaundice in  breast fed infants but also led to  pharmacological variations in drug 
glucuronidation and sometimes unexpected toxicity from therapeutic agents 
(Burchell and Hume, 1999). 
In Liverpool, GS had been studied as the most inherited metabolic liver disorder 
(around 6%) in a Caucasian population (Owens and Evans, 1975). This report had 
been supported that the A (TA)7 TAA mutation in the promoter region is the most 
common cause of GS in Caucasians  (Beutler et al., 1998) compare to Asian 
countries. In Asia, mainly in East Asians countries, it has been proven to be more 
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commonly due to a mutation in exon 1 known as the G71R mutation (Maruo et al., 
1999b). 
1.6.2 Crigler-Najjar Syndrome (CN) 
Crigler-Najjar syndrome (CN) was discovered in 1952 by 2 researchers, Crigler and 
Najjar. CN is also known as congenital non-obstructive non-hemolytic 
hyperbilirubinemia (John F.Crigler, 1952) 
Mutations in the UGT1A1 gene leading to unconjugated bilirubin in CN was first 
reported by Ritter et al in 1992 (Ritter et al., 1992). CN had been classified into two 
types known as Crigler-Najjar Syndrome type I (CN I), discovered by Crigler and 
Najjar and Crigler-Najjar Syndrome type II (CN II) discovered by Arias, based on 
the level of serum bilirubin and the treatments (Arias, 1962). 
CN is marked by partial or total deficiency of the glucuronyl-transferase enzyme and 
might cause fatal hyperbilirubinaemia in neonates if untreated. In severe cases, this 
syndrome may lead to brain damage (kernicterus) to neonates and early screening 
needs to be performed to avoid it. CN can be caused by mutations in intron (non-
coding) or exon (coding) regions of the UGT1A1 gene.  
1.6.2 (i) Crigler-Najjar Syndrome Type I (CN I)      
Crigler Najjar syndrome type I or CN I is inherited in an autosomal recessive way 
and is a rare syndrome (Arias et al., 1969). Studies suggested that CN I is caused by 
a complete absence of UDPGT enzyme activity toward bilirubin in the hepatocytes.  
CN I occurs in 1:1,000,000 newborns and can be observed in the first day of life 
with high levels of serum bilirubin (Labrune, 2004). Neonates with CN I do not 
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respond to phenobarbital treatment. CN I can be caused by several types of mutation 
such as homozygous nonsense, frameshift or homozygous missense mutation 
(Kadakol et al., 2000). CN I is mainly associated with the mutations in exons 2-5 
that might affect the termination codon (Clarke et al., 1997) and premature 
truncation of the UGT1A1 gene (Kadakol et al., 2001). Mutation in CN I was first 
reported in 1992 (Ritter et al., 1992) and CN I can be diagnosed using high-
performance liquid chromatography (HPLC) for analysis of the bile or tissue 
enzyme assay from liver biopsy. A study in 2007 showed that CN I also often 
appeared in the children from consanguineous parents as described in Slovakia‟s 
population (Zmetakova et al., 2007). 
1.6.2 (ii) Crigler-Najjar Syndrome Type II (CN II) 
Crigler- Najjar syndrome type II or CN II is also mainly inherited as an autosomal 
recessive trait (Arias et al., 1969) even though reports of autosomal dominant 
inheritance are available (Arias, 1962).  The serum bilirubin level is markedly 
elevated but less than in CN I (Jansen, 1999).  
Enzyme activity is severely reduced in CN II but it can be induced following 
phenobarbital administration. CN II rarely causes damage to the central nervous 
system (CNS) and the majority of the patients can survive until adulthood without 
any complications. CN II has been more frequently reported in Asian populations as 
compared to other populations (Yamamoto K et al., 1998). 
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1.7 Uridine Diphosphoglucuronate Glucuronosyl Transferase (UDPGT) 1A 
gene 
UDPGT is an enzyme found in many cells in the human body such as the liver, 
intestines, kidneys, lungs and adrenals. Uridine glucuronyl transferases (UGT) 
consist of a large superfamily and are classified into two major isoforms based on 
the nucleotide sequence for the identification of their own isoforms, UGT1 and 
UGT2. These isoforms provide glucuronidation of bilirubin, oestriol, oestradiol, 
quinols and phenols. It represents a super family of microsomal membrane-bound 
enzymes that catalyze conjugation that is not only limited to bilirubin (Kaplan and 
Hammerman, 2005). 
UGT1 encodes a biochemical reaction for the conjugation of glucuronic acid. This 
isoform also mediates glucuronidation of other aglycone substrates in UGT1A locus. 
UGT1A1 is the only isoform that contributes substantially to the bilirubin 
glucuronidation transferase (Kaplan and Hammerman, 2005). 
The length of the gene encoding the UGT1A family is 218kb, consisting of 13 
variable isoforms in exon 1 and all these isoforms are spliced into 4 common exons 
(exon 2 to exon 5). From the 13 variable isoforms, only 9 isoforms encode for 
protein (1A1, 1A3, 1A4, 1A5, 1A6, 1A7, 1A8, 1A9, and 1A10) while another 4 
isoforms are pseudogenes, not functionally important in the UGT1A family (1A2, 
1A11, 1A12 and 1A13). Only variable exon A1 is important in bilirubin conjugation 
and the others play a role in the detoxification of a diverse range of chemical 
substances (Kaplan and Hammerman, 2005). Exons 2 to 5 are responsible in specific 
signal and transcription processing splices of mRNA from single variable exons to 
the common exons.  
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Figure 1.3: Human UGT1 gene locus. 
(a) Schematic representation of the genomic structure of the UGT gene complex.  
(b) Exploded view of exon 1A1 and common exons 2-5 of the gene complex that 
have been identified as sites for genetic mutations associated with absent or 
decreased of UGT activity that cause deficiencies of bilirubin conjugation. Used 
with permission from  Clarke (Clarke et al., 1997) 
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1.8 Bilirubin Uridine Diphosphate-Glucuronosyltransferase 1A1 (UGT1A1) 
gene 
The bilirubin uridine diphosphate-glucuronosyltransferase 1A isoform 1 or UGT1A1 
gene is located in the q arm of chromosome 2, 2q37.1 (see figure 1.4). Other names 
for the UGT1A1 gene include GNT1, Uridine Diphosphate Glucuronosyltransferase 
(UDPGT) and HUG-BR1. It consists of 5 exons (1-5, where exon 1 is spliced to 
exon 2-5) and the specific promoter region. This gene is located at the 3‟ end of the 
UGT1A locus (Costa et al., 2006). 
The common exons in UGT1A family (exons 2-5) are located at 3‟end which encode 
carboxylterminal domain for all UGT isoforms and bind with UDP-glucuronic acids. 
Each isoform in the UGT1A family has the unique exon in exon 1 and also their 
own promoter which is located in the 5‟ N-terminal domain. The UGT1A1 gene has 
an approximate length of about 13 kb (13,027bp) which is not including other genes 
that overlap in the UGT1A family transcripts. Bilirubin uridine diphosphate-
glucuronosyltransferase (B-UGT) is the key enzyme for bilirubin metabolism, and 
decreasing of UGT1A1 gene activity leads to unconjugated hyperbilirubinemia that 
may result in Gilbert Syndrome or Crigler-Najjar Syndrome. Mutations that appear 
in exons and promoter of the UGT1A1 gene may cause structural or functional 
abnormalities of the enzyme, causing impaired bilirubin conjugation, leading to 
hyperbilirubinemia (Kaplan et al., 2003). 
Mutations of the UGT1A1 gene may affect the bilirubin glucuronidation activity that 
is leading to these inherited disorders. Mutation in the promoter region reduces the 
UGT1A1 gene expression while mutation in the coding region cause dysfunction of 
the UGT1A1 gene and also an abnormality of the gene structure (Sun et al., 2007).  
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Figure 1.4 Location of UGT1A1 gene in chromosome 2 (2q37.1) 
Adapted from: 
http://www.ensembl.org/Homo_sapiens/Location/Chromosome?g=ENSG00000241
635;r=2:234669368-234682419;t=ENST00000305208 
 
 
 
Location of 
UGT1A1 gene 
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1.9 Mutations in the UGT1A1 gene 
Mutations of the UGT1A1 gene can be classified into three groups:  
 
1. Mutations that result in reduced production of the enzyme (Guillemette C., 
2003). 
2.  Mutations that give rise to the synthesis of an enzyme that is structurally 
and/or functionally abnormal (Sampietro M et al., 2003).  
3. Mutations which completely abolish the expression of the affected allele 
(Sampietro M et al., 1999).   
 
Mutation is defined as a permanent change in the genome, either in DNA or RNA 
sequence which cause changes in amino acids or proteins related to that particular 
gene. Mutations may occur due to radiation, viruses and mutagenic chemicals which 
cause errors during meiosis or DNA replication (Bertram, 2001). 
 
Mutations in the UGT1A1 gene occur in the coding region, known as exon and in the 
non coding region, known as intron. Since in the middle of 1980s more prevalence 
of mutations in the UGT1A1 gene had been discovered and mutation that is 
responsible for Gilbert syndrome was first described in 1995 by Aono et al (Aono et 
al., 1995).  
 
As discussed above (section on Gilbert Syndrome), an important mutation in 
Caucasians is located in the promoter region. Association of mutations in the 
promoter region and enhancer region have been found to be significant risk factors 
for NNJ (Bosma et al., 1995) (Yamamoto et al., 2002) and recently this has also 
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been confirmed in a Malay population (Yusoff S, 2010). The focus of the current 
study is however on the exonic region of the UGT1A1 gene. 
 
One of the exonic mutations that seems to play a real important role in neonatal 
jaundice in Asians (Long et al., 2011) is the G71R mutation. It is a common 
mutation of the UGT1A1 gene and has been widely reported in East Asian countries 
such as Taiwan, China and Japan. 
 
In Southeast Asian populations, this mutation of the UGT1A1 gene was believed to 
be first described in a Thai population (Sutomo et al., 2002). Other reports about 
Southeast Asia include studies done in Singapore (Zhou et al., 2009), Indonesia 
(Sutomo et al., 2004) and Malaysia (Yusoff et al., 2006) (Boo et al., 2009). The 
findings in each of these studies are compared to the findings in the current study in 
the discussion part of this thesis. The G71R mutation is located in exon 1 of the 
UGT1A1 gene and comprises of a substitution of Guanine to Adenine (G to A) at 
nucleotide 211. It causes a change of amino acids from glycine to arginine at codon 
71 (G71R). The G71R mutation  seems to be rare in Caucasian populations (Narter 
et al., 2011) and because of the high prevalence of this mutation, in Asian 
population, it had been considered as polymorphism for Asian people (Takeuchi et 
al., 2004). 
 
A study in Japan showed that the G71R mutation, either in heterozygous or 
homozygous trait, may decrease the enzyme activity by 32.2% and 60.2% 
respectively using in- vitro expression (Yamamoto et al., 1998). This condition may 
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lead from mild to moderate delay of bilirubin elimination in human (Sun et al., 
2007). 
 
Another major mutation in Asian populations, mainly in the Japanese population, 
related to NNJ is the P229Q or Pro229Gln mutation which is also located at exon 1 
of the UGT1A1 gene. This mutation causes substitution of nucleotide Cytosine (C) 
to Adenine (A) at nucleotide 686 (Saeki et al., 2003). There are studies suggesting 
that a combination of mutations (TATA box with G71R or P229Q) increases the 
serum bilirubin levels in neonates (Kamisako, 2004). 
However, a study in Taiwan suggested that the combination of promoter or G71R 
and P229Q might not affect the serum bilirubin level significantly in neonates 
(Hsieh et al., 2001).  
 
As mutation at the same codon has also been observed in African-American 
population but a different nucleotide was involved. It caused a change of nucleotide 
from Cytosine (C) to Thymine (T) and is known as P229L, causing an amino acid 
change from Proline to Leucine (Kaniwa et al., 2005b).  
 
Besides G71R and P229Q mutations in exon 1, the Y486D in exon 5 of the UGT1A1 
gene had been suggested to contribute in the development of neonatal jaundice 
(Takeuchi et al., 2004). The Y486D mutation causes a substitution of nucleotides 
(from Thymine (T) to Guanine (G) at position number 1456, leading to an amino 
acid change, Tyr486Asp. This results in  a decrease of 7% of the UGT1A1 gene 
enzyme function (Wu et al., 2008).  
